{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:35:45Z","timestamp":1792121745082,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01381-y","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:21:21Z","timestamp":1764001281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7615-0572","authenticated-orcid":false,"given":"Monia","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro Maria","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John O.","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-4619","authenticated-orcid":false,"given":"Alberto","family":"Alvarez-Larran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-1676","authenticated-orcid":false,"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3212-920X","authenticated-orcid":false,"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u0171diger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-6327","authenticated-orcid":false,"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"1381_CR1","doi-asserted-by":"publisher","unstructured":"Marchetti M. Ph-negative myeloproliferative neoplasms. In: Rezaei N, editor. Comprehensive hematology and stem cell resource. Elsevier Reference Collection in Biomedical Sciences. 2023. https:\/\/doi.org\/10.1012\/B978-0-443-15717-2.00015-9","DOI":"10.1012\/B978-0-443-15717-2.00015-9"},{"key":"1381_CR2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jama.2024.15219","volume":"332","author":"RS Taylor","year":"2024","unstructured":"Taylor RS, Manyara AM, Ross JS, Ciani O. Surrogate end points in trials\u2014SPIRIT and CONSORT extensions. JAMA. 2024;332:1340.","journal-title":"JAMA"},{"key":"1381_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/cid\/civ495","volume":"61","author":"SR Evans","year":"2015","unstructured":"Evans SR, Rubin D, Follmwn D, et al. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015;61:800\u20136.","journal-title":"Clin Infect Dis"},{"key":"1381_CR4","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf Accessed 31st August."},{"key":"1381_CR5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703.","journal-title":"Leukemia"},{"key":"1381_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasniscka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200.","journal-title":"Blood"},{"key":"1381_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Subcommittee on control of anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692.","journal-title":"J Thromb Haemost"},{"key":"1381_CR8","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395.","journal-title":"Blood"},{"key":"1381_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057.","journal-title":"Leukemia"},{"key":"1381_CR10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/leu.2016.283","volume":"31","author":"M Marchetti","year":"2017","unstructured":"Marchetti M, Barosi G, Cervantes F, Birgegard G, Griesshammer M, Harrison C, et al. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia. 2017;31:882.","journal-title":"Leukemia"},{"key":"1381_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jval.2024.01.014","volume":"27","author":"S Hudgens","year":"2024","unstructured":"Hudgens S, Verstovsek S, Floden L, Harrison CN, Palmer J, Gupta V, et al. Meaningful symptomatic change in patients with myelofibrosis from the SIMPLIFY studies. Value Health. 2024;27:607\u201313.","journal-title":"Value Health"},{"key":"1381_CR12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31:1285.","journal-title":"J Clin Oncol"},{"key":"1381_CR13","doi-asserted-by":"publisher","first-page":"ofad500.439","DOI":"10.1093\/ofid\/ofad500.439","volume":"10","author":"T Hamasaki","year":"2023","unstructured":"Hamasaki T, He Y, Evans SR. The DOOR is open: a web-based application for analyzing the Desirability of Outcome Ranking. Open Forum Infect Dis. 2023;10:ofad500.439.","journal-title":"Open Forum Infect Dis"},{"key":"1381_CR14","doi-asserted-by":"publisher","first-page":"100364","DOI":"10.1016\/j.jcpo.2022.100364","volume":"34","author":"A Walia","year":"2022","unstructured":"Walia A, Haslam A, Prasad V. FDA validation of surrogate endpoints in oncology: 2005-2022. J Cancer Policy. 2022;34:100364.","journal-title":"J Cancer Policy"},{"key":"1381_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2217\/fon-2023-0964","volume":"20","author":"BJ Klencke","year":"2024","unstructured":"Klencke BJ, Donahue R, Gorsh B, Ellis C, Kawashima J, Strouse B. Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus. Future Oncol. 2024;20:703.","journal-title":"Future Oncol"},{"key":"1381_CR16","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S2352-3026(24)00067-X","volume":"11","author":"G Barosi","year":"2024","unstructured":"Barosi G, Tefferi A, Gangat N, Szuber N, Rambaldi A, Odenike O, et al. Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024;11:e383.","journal-title":"Lancet Haematol"},{"key":"1381_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/cid\/ciad576","volume":"78","author":"J Howard-Anderson","year":"2024","unstructured":"Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, et al. Moving beyond mortality: development and application of a desirability of outcome ranking (DOOR) endpoint for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2024;78:259.","journal-title":"Clin Infect Dis"},{"key":"1381_CR18","first-page":"21","volume":"13","author":"P Guglielmelli","year":"2023","unstructured":"Guglielmelli P, Maccari C, Sordi B, Balliu M, Atanasio A, Mannarelli C, et al. Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. Blood. Cancer J. 2023;13:21.","journal-title":"Cancer J"},{"key":"1381_CR19","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","volume":"114","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAV2V617F mutate allele. Blood. 2009;114:1477.","journal-title":"Blood"},{"key":"1381_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jha2.854","volume":"5","author":"ST Oh","year":"2024","unstructured":"Oh ST, Verstovsek S, Gupta V, Platzbecker U, Devos T, Kiladjian J-J, et al. Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis. eJHaem. 2024;5:105.","journal-title":"eJHaem"},{"key":"1381_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41375-022-01773-0","volume":"37","author":"H Ryou","year":"2023","unstructured":"Ryou H, Sirinukunwattana K, Aberdeen A, Grindstaff G, Stolz BJ, Byrne H, et al. Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients. Leukemia. 2023;37:348.","journal-title":"Leukemia"},{"key":"1381_CR22","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","volume":"9","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, et al. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol. 2022;9:e434.","journal-title":"Lancet Haematol"},{"key":"1381_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ajh.25700","volume":"95","author":"M Marchetti","year":"2020","unstructured":"Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, et al. Second cancers in MPN: a survival analysis from an international study. Am J Hematol. 2020;95:295.","journal-title":"Am J Hematol"},{"key":"1381_CR24","doi-asserted-by":"publisher","first-page":"204062072311547","DOI":"10.1177\/20406207231154706","volume":"14","author":"M Marchetti","year":"2023","unstructured":"Marchetti M, Salamanton-Garc\u00eca J, El-Ashwah S, Verga L, Itri F, Racil Z, et al. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry. Ther Adv Hematol. 2023;14:20406207231154706.","journal-title":"Ther Adv Hematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01381-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01381-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01381-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:18:07Z","timestamp":1769617087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01381-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01381-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6785954\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The correct affiliation for professor Prithviraj Bose is: 5 Department of Leukemia, University of Texas MD Anderson Cancer Center. Prithviray Bose\u2019s affiliation was erroneously reported as \u201c5Wake Forest University School of Medicine, Winston Salem, NC, USA.\u201d","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MM was a consultant to Gilead, Novartis, Roche, Menarini, and GSK. MM received support for meeting participation from AbbVie and Roche. MM is a member of The Methodology Team for Guideline Development of the Italian Society of Hematology and a PLOS-ONE Academic Associate Editor. AMV received speaker honoraria from Incyte, AbbVie, Novartis, BMS, AOP, ITF, and participated in Safety or Advisory Boards for Incyte, Novartis, and BMS. JM received grants from Incyte, Novartis, AbbVie, BMS, CTI\/SOBI, Karyopharm, Geron, Kartos, and PharmaEssentia and consulting fees from Incyte, Novartis, AbbVie, BMS, CTI\/SOBI, Karyopharm, Geron, Kartos, Roche, Mark, GSK, Disc, PharmEssentia, MorphoSys, and Keros. AAL received honoraria for lectures from AOP and GSK and consulting fees from AOP. PB received grants from Incyte, BMS, CTI\/SOBI, Morphosys, Kartos, telios, Janssen, Geron, Ionis, Disc, Karyopharm, Sumitomo, Ajax, Blueprint, Cogent, and consulting fees from Incyte, BMS, CTI\/SOBI, GSK, AbbVie, Morphosys, PharaEssentia, Ionis, Disc, Karyopharm, Sumitomo, Geron, Morphic, Jubilant, Keros, Ono, Raythera, Novartis, Blueprint, Cogent. RPG is a consultant to Antengene Biotech LLC; Medical Director, FFF Enterprises Inc.; A speaker for Janssen Pharma and Hengrui Pharma; Board of Directors: Russian Foundation for Cancer Research Support and Scientific Advisory Board, StemRad Ltd. CH received consulting fees from Sobi, Merck, GSK, OPNA Bio, Incyte, BMS, Alethiomics, CTI, Silence Therapeutics, Karyopharm, Galecto, Mennari Stemline, DISC, Keros, Morphosys, Novartis. CH also received honoraria for lectures from Novartis, GSK, Merck, Menarini Stemline, AOP, BMS, Incyte, Morphosys, and support for attending meetings from Novartis. CH disclaims her leadership role for MPN Voice and Blood Cancer UK. RH does not disclose any COI. JJK participated in Safety or Advisory Boards for Incyte and BMS and received support for meeting attendance from Novartis. JJK received honoraria as a speaker from AOP and PharmaEssenti and consulting fees from GSK, Novartis, and AbbVie. Gilead, Jazz, Omeros, Sanofi, Italfarmaco. SK received consulting fees from Novartis, BMS, Incyte \/Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Karthos, Sierra Oncology, Glaxo-Smith Kline (GSK), Imago Biosciences, AbbVie, MSD, iOMEDICO. SK also received speaker honoraria from Novartis, BMS, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, Janssen, Geron, Celgene, Karthos, AbbVie, iomedico, GSK, MSD, and payment for expert testimony from Novartis and GSK. SK received support for meeting attendance from Alexion, Novartis, BMS, Celgene, Incyte, Ariad, AOP Pharma, CTI, Pfizer, Sanofi, Janssen, Geron, Imago Biosciences, GSK, PharmaEssentia, Sierra, Oncology, AbbVie, iOMEDICO, and MSD. SK has a patent for a BET inhibitor drug for RWTH Aachen University. SK joined Safety or Advisory Boards for Pfizer, Incyte\/Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, MPN Hub, Sierra Oncology, Glaxo-Smith Kline, and AbbVie. SK is Chairman of the Hemostasis Working Party of German Society of Hematology and Medical Oncology (DGHO), Speaker of German Study Group of MPN (GSG-MPN), Member of Guidelines Committee of European Haematology Association (EHA), and Associate Editor for Hemasphere journal. RM did not disclose any COI. FP received honoraria for lectures from Novartis, Bristol-Myers, Squibb, Abbvie, GSK, Janssen, AOP Orphan, Novartis, Bristol-Myers, Squibb, AbbVie, GSK, Janssen, AOP Orphan, and Jazz. FP also participated in Safety Monitoring Boards or Advisory Boards for Novartis, Bristol-Myers, Squibb\/ Celgene, GSK, AbbVie, AOP Orphan, Janssen, Sumitomo, and Kartos. AR participated in Safety Monitoring Boards or Advisory Boards for Amgen, Novartis, and Kite. AT did not disclose any COI. TB did not disclose any COI.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was not needed since patients\u2019 data were not managed, nor tests or treatments performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"207"}}